• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Slowing Progression in CKD: DAPA CKD and Beyond.慢性肾脏病进展的延缓：达格列净治疗慢性肾脏病及其他相关研究
Clin J Am Soc Nephrol. 2021 Jul;16(7):1117-1119. doi: 10.2215/CJN.20211220. Epub 2021 Mar 10.
2
Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.钠-葡萄糖共转运蛋白 2 抑制剂和非甾体类盐皮质激素受体拮抗剂：在肾素-血管紧张素系统阻断之外开创肾脏保护的新时代。
Nephrology (Carlton). 2021 Nov;26(11):858-871. doi: 10.1111/nep.13917. Epub 2021 Jul 6.
3
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.达格列净与慢性肾脏病不良结局预防（DAPA-CKD）试验：基线特征。
Nephrol Dial Transplant. 2020 Oct 1;35(10):1700-1711. doi: 10.1093/ndt/gfaa234.
4
Developing Treatments for Chronic Kidney Disease in the 21st Century.21世纪慢性肾脏病的治疗进展
Semin Nephrol. 2016 Nov;36(6):436-447. doi: 10.1016/j.semnephrol.2016.08.001.
5
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.达格列净对伴有和不伴有 2 型糖尿病的慢性肾脏病患者肾功能下降速率的影响：来自 DAPA-CKD 试验的预先指定分析。
Lancet Diabetes Endocrinol. 2021 Nov;9(11):743-754. doi: 10.1016/S2213-8587(21)00242-4. Epub 2021 Oct 4.
6
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.达格列净和预防慢性肾脏病不良结局（DAPA-CKD）随机对照试验的原理和方案。
Nephrol Dial Transplant. 2020 Feb 1;35(2):274-282. doi: 10.1093/ndt/gfz290.
7
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.达格列净对伴有和不伴有 2 型糖尿病的慢性肾脏病患者尿白蛋白排泄的影响：来自 DAPA-CKD 试验的预设分析。
Lancet Diabetes Endocrinol. 2021 Nov;9(11):755-766. doi: 10.1016/S2213-8587(21)00243-6. Epub 2021 Oct 4.
8
DAPA-CKD: Significant Victory for CKD with or without Diabetes.达格列净治疗慢性肾脏病（DAPA-CKD）：无论有无糖尿病的慢性肾脏病的重大胜利。
Trends Endocrinol Metab. 2021 Jun;32(6):335-337. doi: 10.1016/j.tem.2021.02.007. Epub 2021 Mar 4.
9
Effects of dapagliflozin on renin-angiotensin-aldosterone system under renin-angiotensin system inhibitor administration.达格列净对肾素-血管紧张素-醛固酮系统抑制剂治疗下肾素-血管紧张素-醛固酮系统的影响。
Endocr J. 2020 Nov 28;67(11):1127-1138. doi: 10.1507/endocrj.EJ20-0222. Epub 2020 Jul 1.
10
TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.塔勒氏肽酶和慢性肾病中的肽酶抑制作用。
Curr Opin Nephrol Hypertens. 2021 Jan;30(1):123-130. doi: 10.1097/MNH.0000000000000659.

引用本文的文献

1
Trends in Co-morbid Dementia and Chronic Kidney Disease.共病性痴呆与慢性肾脏病的趋势
J Gen Intern Med. 2025 Jan 14. doi: 10.1007/s11606-024-09069-y.
2
Chronic Kidney Disease in Brazil: Current Status and Recommended Improvements.巴西的慢性肾脏病：现状与建议改进措施
Kidney Dis (Basel). 2024 Feb 29;10(3):213-223. doi: 10.1159/000538068. eCollection 2024 Jun.
3
Overcoming barriers to deliver high quality kidney care.克服提供高质量肾脏护理的障碍。
Nat Rev Nephrol. 2024 Mar;20(3):149-150. doi: 10.1038/s41581-024-00807-3.
4
CHA2DS2VASc score predicts risk of end stage renal disease in patients with atrial fibrillation: Long-term follow-up study.CHA2DS2VASc评分可预测心房颤动患者终末期肾病风险：一项长期随访研究。
Heliyon. 2023 Feb 22;9(3):e13978. doi: 10.1016/j.heliyon.2023.e13978. eCollection 2023 Mar.
5
Cardiac Valve Disease and Prevalent and Incident CKD in Community-Dwelling Older Adults: The Atherosclerosis Risk in Communities (ARIC) Study.社区居住的老年人中心脏瓣膜疾病与慢性肾脏病的患病率和发病率：社区动脉粥样硬化风险（ARIC）研究
Kidney Med. 2022 Oct 15;4(12):100559. doi: 10.1016/j.xkme.2022.100559. eCollection 2022 Dec.
6
Soluble urokinase plasminogen activator receptor and decline in kidney function among patients without kidney disease.可溶性尿激酶型纤溶酶原激活物受体与无肾脏疾病患者的肾功能下降
Clin Kidney J. 2022 Feb 21;15(8):1534-1541. doi: 10.1093/ckj/sfac048. eCollection 2022 Aug.
7
A real-world study on SGLT2 inhibitors and diabetic kidney disease progression.一项关于钠-葡萄糖协同转运蛋白2抑制剂与糖尿病肾病进展的真实世界研究。
Clin Kidney J. 2022 Feb 16;15(7):1403-1414. doi: 10.1093/ckj/sfac044. eCollection 2022 Jul.

Slowing Progression in CKD: DAPA CKD and Beyond.

作者信息

Larmour Kathryn, Levin Adeera

机构信息

Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada.

出版信息

Clin J Am Soc Nephrol. 2021 Jul;16(7):1117-1119. doi: 10.2215/CJN.20211220. Epub 2021 Mar 10.

DOI:10.2215/CJN.20211220
PMID:33692116
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8425615/
Abstract
摘要